Interventional Clinical Trial
Official title:
The Effect of Exercise and Presleep Nutrition on Muscle Connective Tissue Remodelling
NCT number | NCT06054620 |
Other study ID # | CVC |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | September 15, 2023 |
Est. completion date | August 1, 2025 |
The primary objective of this study will be to determine the influence of a presleep vitamin C-enriched, collagen-modelled supplement (CVC) on the metabolic fate of dietary glycine using a [2H5]glycine tracer within the intramuscular connective tissue at rest and after a bout of resistance exercise. Other outcomes will be related to regulation collagen remodelling in skeletal muscle.
Status | Recruiting |
Enrollment | 12 |
Est. completion date | August 1, 2025 |
Est. primary completion date | September 1, 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 35 Years |
Eligibility | Inclusion Criteria: - Healthy, recreationally active, male and female participants. - Healthy will be defined as someone who does not have a health condition that would compromise their ability to safely participate in the strenuous physical activity involved in our study as screened for by the Get Active Questionnaire. - Willing to abstain from resistance exercise for 2 weeks prior to the first metabolic trial and for the duration of the study. - Participants must be able to abstain from lower-body resistance and/or plyometric exercise for at least 2 weeks prior to the first metabolic trial. - Participants will be aged 18-35 years old. - Participants must be normal to overweight (e.g., BMI 18.5-30). - Participants are willing to abide by the compliance rules of this study (e.g., abstain from physical activity and alcohol 48h prior to each trial). - Self-reported regular menstrual cycle (25-35d) within the last 3 months (female participants). Exclusion Criteria: - Inability to adhere to any of the compliance rules judged by principal investigator or medical doctor. - Self-reported regular tobacco use. - Self-reported illicit drug use (e.g. growth hormone, testosterone, etc.). - Regular use of anti-inflammatory drugs (e.g., ibuprofen). - Self-reported regularly sleeping less than an average of 7 hours over 3 days (minimum recommended daily amount). - Individuals who have participated in studies within the past year involving any of the stable isotopes in the study. - Use of birth control and discontinued use in the last 3-months (female only). |
Country | Name | City | State |
---|---|---|---|
Canada | Goldring Centre for High Performance Sport at the University of Toronto | Toronto | Ontario |
Lead Sponsor | Collaborator |
---|---|
University of Toronto |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Intensity of Muscle Soreness | Subjective muscle soreness will be quantified using a visual analog scale on trial day mornings and evenings as well as before and after exercise. Using a line spanning 0 to 100 (100 being greatest soreness), participants will select a spot on the line indicating their subjective muscle soreness. | 24 hours | |
Primary | Enrichment of Muscle Collagen | Overnight incorporation of orally ingested amino acid tracer (D5 Gly and D5 Phe) into mature collagen protein isolated from skeletal muscle biopsy samples taken 9 hours after consumption of the tracer-containing supplement (CVC or PLA) and rest or resistance exercise. Enrichment will be quantified via tandem LC-MS/MS. | 9 hours | |
Secondary | Area of muscle with localized collagen remodelling | Immunofluorescence determined localization of collagen breakdown and synthesis using collagen hybridizing peptide and procollagen antibodies, respectively, on human skeletal muscle cross-sections. | 9 hours | |
Secondary | Concentration of Urinary Growth Hormone | Urine will be collected overnight to measure growth hormone secretion using chemiluminescence. | 8 hours | |
Secondary | Enrichment of Myofibrillar Protein | Overnight incorporation of orally ingested amino acid tracer (D5 Gly and D5 Phe) into myofibrillar proteins isolated from skeletal muscle biopsy samples taken 9 hours after consumption of the tracer-containing supplement (CVC or PLA) and rest or resistance exercise. Enrichment will be quantified via tandem LC-MS/MS. | 9 hours |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05336708 -
The Effect of Acupressure on Fatigue
|
N/A | |
Recruiting |
NCT05060484 -
A Phase II Study of SCT1000 in Healthy Women Aged 18 to 45 Years
|
Phase 2 | |
Active, not recruiting |
NCT05554653 -
Influence of Leucine Enriched Amino Acids on Myofibrillar and Collagen Protein Synthesis
|
N/A | |
Completed |
NCT03756935 -
Early Detection of Intra Operative Hypotension (IOH) During the Induction of General Anaesthesia
|
||
Recruiting |
NCT05145712 -
Quantitative Bowel Readiness Assessment System in Predicting the Missed Detection Rate of Adenomas
|
N/A | |
Not yet recruiting |
NCT06468046 -
Mama Empoderada: Adapting a Novel Mental Health Prevention Intervention for Migrant Mothers With Young Children
|
N/A | |
Completed |
NCT03853226 -
Rational for the Use of Velocity-Pressure Loop in the Operating Room
|
||
Recruiting |
NCT03921164 -
Non Invasive Use of Pressure-Volume Loop in the Operating Room
|
||
Completed |
NCT03876379 -
Brain Power Spectral Density Under Propofol
|
||
Active, not recruiting |
NCT05754125 -
In Vivo and in Vitro Anabolic Potential of Essential Amino Acids Following Resistance Exercise
|
N/A | |
Recruiting |
NCT02778724 -
France PCI Registry : National Observatory of Interventional Cardiology
|
||
Terminated |
NCT03585855 -
Mesenchymal Stem Cell Transplantation in the Treatment of Chronic Antibody Mediated Kidney Graft Rejection (ABMR)
|
N/A | |
Completed |
NCT03769142 -
Cerebral Perfusion During Induction of General Anesthesia
|